Inotai A - Search Results

1

Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology.

Inotai A, Pékli M, Jóna G, Nagy O, Remák E, Kaló Z. Inotai A, et al. BMC Health Serv Res. 2012 Sep 21;12:332. doi: 10.1186/1472-6963-12-332. BMC Health Serv Res. 2012. PMID: 22999574 Free PMC article. Review.

2

Corrigendum to "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications".

Godman B, Wladysiuk M, McTaggart S, Kurdi A, Allocati E, Jakovljevic M, Kalemeera F, Hoxha I, Nachtnebel A, Sauermann R, Hinteregger M, Marković-Peković V, Tubic B, Petrova G, Tachkov K, Slabý J, Nejezchlebova R, Krulichová IS, Laius O, Selke G, Langner I, Harsanyi A, Inotai A, Jakupi A, Henkuzens S, Garuolienė K, Gulbinovič J, Bonanno PV, Rutkowski J, Ingeberg S, Melien Ø, Mardare I, Fürst J, MacBride-Stewart S, Holmes C, Pontes C, Zara C, Pedrola MT, Hoffmann M, Kourafalos V, Pisana A, Banzi R, Campbell S, Wettermark B. Godman B, et al. Among authors: inotai a. Biomed Res Int. 2023 Apr 7;2023:9757348. doi: 10.1155/2023/9757348. eCollection 2023. Biomed Res Int. 2023. PMID: 37065720 Free PMC article.

3

[Decision analytic modeling and their impact on health care decision making].

Inotai A, Kaló Z, Mészáros A. Inotai A, et al. Acta Pharm Hung. 2009;79(2):63-9. Acta Pharm Hung. 2009. PMID: 19634636 Hungarian.

4

[Assessment of the pharmaceutical expenditure in Hungary].

Inotai A, Merész G, Kaló Z. Inotai A, et al. Acta Pharm Hung. 2010;80(4):162-72. Acta Pharm Hung. 2010. PMID: 21404477 Hungarian.

5

[Risk sharing methods in middle income countries].

Inotai A, Kaló Z. Inotai A, et al. Acta Pharm Hung. 2012;82(1):43-52. Acta Pharm Hung. 2012. PMID: 22570986 Review. Hungarian.

6

Benefits of investment into modern medicines in Central-Eastern European countries.

Inotai A, Petrova G, Vitezic D, Kaló Z. Inotai A, et al. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):71-9. doi: 10.1586/14737167.2014.868314. Epub 2013 Dec 19. Expert Rev Pharmacoecon Outcomes Res. 2014. PMID: 24350863 Review.

7

Need for multicriteria evaluation of generic drug policies.

Kaló Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A, Brixner D. Kaló Z, et al. Among authors: inotai a. Value Health. 2015 Mar;18(2):346-51. doi: 10.1016/j.jval.2014.12.012. Epub 2015 Feb 11. Value Health. 2015. PMID: 25773570 Free article. Review.

8

Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.

Inotai A, Prins CPJ, Csanádi M, Vitezic D, Codreanu C, Kaló Z. Inotai A, et al. Expert Opin Biol Ther. 2017 Aug;17(8):915-926. doi: 10.1080/14712598.2017.1341486. Epub 2017 Jun 26. Expert Opin Biol Ther. 2017. PMID: 28650704 Review.

9

Osteoporotic fractures may impair life as much as the complications of diabetes.

Vokó Z, Gáspár K, Inotai A, Horváth C, Bors K, Speer G, Kaló Z. Vokó Z, et al. Among authors: inotai a. J Eval Clin Pract. 2017 Dec;23(6):1375-1380. doi: 10.1111/jep.12800. Epub 2017 Sep 12. J Eval Clin Pract. 2017. PMID: 28895276

10

Overview on Patient Centricity in Cancer Care.

Narbutas Š, York K, Stein BD, Magsanoc-Alikpala K, Majima Y, Kalo Z, Almasi T, Inotai A. Narbutas Š, et al. Among authors: inotai a. Front Pharmacol. 2017 Oct 5;8:698. doi: 10.3389/fphar.2017.00698. eCollection 2017. Front Pharmacol. 2017. PMID: 29051734 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page